8-K: Syra Health Corp. Receives Nasdaq Delisting Notice Due to Low Share Price

Syra Health Corp. has been notified by Nasdaq that its stock price has fallen below the minimum $1.00 requirement for continued listing.

Summary

• Syra Health Corp. received a notice from Nasdaq on October 18, 2024, stating that its stock price has closed below $1.00 for the past 30 consecutive business days.
• This non-compliance with Nasdaq Listing Rule 5550(a)(2) puts the company at risk of being delisted from the Nasdaq Capital Market.
• Syra Health has 180 calendar days, until April 16, 2025, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If the company fails to meet this requirement, it may be eligible for a second 180-day compliance period.
• Failure to regain compliance during either period could lead to delisting, which the company could appeal.
• The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern for investors.

Positives

• The company has been given 180 days to regain compliance, providing an opportunity to rectify the situation.
• There is a possibility of a second 180-day compliance period if the initial deadline is not met.
• The company intends to actively monitor the situation and consider options to regain compliance.

Negatives

• The company's stock price has fallen below the minimum $1.00 requirement for continued listing on the Nasdaq Capital Market.
• There is a risk of delisting if the company fails to regain compliance within the given timeframes.
• There is no guarantee that the company will be successful in maintaining its listing on the Nasdaq Capital Market.

Risks

• The primary risk is the potential delisting from the Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement.
• The company's stock price may be volatile due to the uncertainty surrounding its listing status.
• There is no assurance that the company will be able to implement effective measures to increase its stock price.

Future Outlook

The company intends to actively monitor its stock price and may consider implementing available options to regain compliance with the minimum bid price under the Nasdaq Listing Rules, but there is no assurance of success.

Management Comments

• The company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price under the Nasdaq Listing Rules.

Industry Context

This announcement is not specific to the industry but rather a company-specific issue related to maintaining listing requirements on the Nasdaq exchange. Many companies face similar challenges when their stock price declines.

Comparison to Industry Standards

• Many companies listed on exchanges like Nasdaq are required to maintain a minimum share price to remain listed.
• Failure to meet these requirements can lead to delisting, which is a common issue for companies with declining stock prices.
• Other companies that have faced similar delisting notices include those in the biotech and small-cap sectors, where stock price volatility is common.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in the value of their investment.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• The company will actively monitor its stock price.
• The company may consider options to regain compliance with Nasdaq listing rules.
• The company must achieve a stock price of $1.00 or more for at least ten consecutive business days by April 16, 2025, to avoid delisting.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, SYRA, listing rule